Determination of best candidates for novel orally delivered therapeutic candidates to combat spread of coccidiosis in poultry

Award Information
Agency: Department of Agriculture
Branch: N/A
Contract: 2015-33610-23499
Agency Tracking Number: 2015-00407
Amount: $98,481.00
Phase: Phase I
Program: SBIR
Awards Year: 2015
Solicitation Year: 2015
Solicitation Topic Code: 8.3
Solicitation Number: N/A
Small Business Information
20 DUDLEY ST STE 900, Memphis, TN, 38103-0000
DUNS: 078490572
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Douglas Zatechka
 Chief Operating Officer
 (901) 755-6868
 steve.zatechka@usbiologic.com
Business Contact
 Chris Przybyszewski
Title: Executive Vice President
Phone: (901) 490-5857
Email: chris.przybyszewski@usbiologic.com
Research Institution
N/A
Abstract
Avian coccidiosis is the major parasitic disease of poultry that can result in the deaths of millions of birds in a short time. Prophylactic medication and live parasite vaccines are employed as therapeutics. The development of parasite strains resistant to drug treatments, and immune-evasive mutations introduced in response to live parasite treatments will soon limit the effectiveness. The USDA Agricultural Research Service (ARS) has developed three promising candidate therapeutics, NK-lysin (treatment), cNK-2 (treatment - single biopeptide of NK-Lysin), and 3-1e (vaccine) that circumvent such issues. Without a safe, effective, and cost-efficient delivery method, these therapeutics remain impractical. One opportunity is to combine the formulations with an oral-delivery platform such as one developed by US BIOLOGIC. The entities have entered into a research partnership to combine these technologies to utilize an intestine-targeted delivery vector carrying NK-lysin, cNK-2, and/or 3-1e genes in a novel oral delivery formulation that will lead to enhanced host immunity to coccidiosis to reduce gut damage caused by intracellular parasitism. The goal of this project is the development of a stable vaccine or treatment-coated chicken feed that will control coccidiosis infection upon an administered challenge. To determine the most viable candidate of the three, the researchers will create in silico models of each, engineer each in liquid form, and then administer the gavages in a small-scale poultry study at the ARS. A successfully commercialized product would offer a transformative tool for poultry farmers to limit destruction caused by coccidiosis, encouraging better food security, and limiting threats from bioterrorism.

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government